DUBLIN--(BUSINESS WIRE)--The "Glioblastoma Multiforme Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering.
The global glioblastoma multiforme treatment market is expected to grow at a CAGR of around 11% during 2019-2024.
Glioblastoma multiforme, also known as grade IV astrocytoma, is a malignant grade IV brain tumor that rapidly spreads within the brain cells and can also infect the nearby cells. Since it is characterized by rapid cell degeneration, it creates immense pressure on the brain resulting in severe headaches and seizures. Although the exact cause of the diseases is still unknown, several factors including rare hereditary disorders such as Turcot syndrome are believed to be its cause. It is one of the most lethal forms of brain cancer and is treatment-resistant in nature, wherein the patient has an extremely short survival period post-diagnosis. The current treatment procedure of the disease includes surgical resection, chemotherapy and radiation.
Increasing prevalence of oncological diseases and a growing geriatric population across the globe are among the key factors driving the market growth. Furthermore, the development of advanced treatment methods that counter the resistive properties of glioma stem cells is also positively influencing the market growth.
Additionally, increasing research and development (R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated the development of various biological drugs. These drugs assist in diminishing the side-effects of the existing treatment methods, thus creating broader acceptance amongst patients. Moreover, initiatives undertaken by several governments across the globe to improve healthcare infrastructure, along with the rising awareness of the availability of various therapies, are further expected to create a positive outlook for the market.
Key Questions Answered in This Report:
How has the global glioblastoma multiforme treatment market performed so far and how will it perform in the coming years?
What are the key regional markets in the global glioblastoma multiforme treatment industry?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the route of administration?
What is the breakup of the market based on the type of molecule?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the global glioblastoma multiforme treatment industry?
What are the key driving factors and challenges in the global glioblastoma multiforme treatment industry?
What is the structure of the global glioblastoma multiforme treatment industry and who are the key players?
What is the degree of competition in the global glioblastoma multiforme treatment industry?
Key Topics Covered:
2 Scope and Methodology
2.1 Objectives of the Study
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4.2 Key Industry Trends
5 Global Glioblastoma Multiforme Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Market Breakup by Drug Type
5.4 Market Breakup by Route of Administration
5.5 Market Breakup by Type of Molecule
5.6 Market Breakup by Distribution Channel
5.7 Market Breakup by Region
5.8 Market Forecast
6 Market Breakup by Drug Type
6.1.1 Market Trends
6.1.2 Market Forecast
7 Market Breakup by Route of Administration
7.1.1 Market Trends
7.1.2 Market Forecast
8 Market Breakup by Type of Molecule
8.1 Small Molecule
8.1.1 Market Trends
8.1.2 Market Forecast
9 Market Breakup by Distribution Channel
9.1.1 Market Trends
9.1.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 Market Trends
10.1.2 Market Forecast
10.3 Asia Pacific
10.4 Middle East and Africa
10.5 Latin America
11 SWOT Analysis
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Sun Pharmaceutical Industries
15.3.2 Celldex Therapeutics
15.3.4 F.Hoffmann La Roche
15.3.5 Bristol-Myers Squibb
15.3.6 Teva Pharmaceuticals
15.3.9 Arbor Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/ou2vdj